Gilead Continues Immuno-oncology Spree with US$21 B Immunomedics Buy
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 9 (Table of Contents)
Published: 18 Sep-2020
DOI: 10.3833/pdr.v2020.i9.2562 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In the largest M&A deal of 2020 so far, Gilead Sciences has agreed to pay US$21 B to acquire Immunomedics, a biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS